Schonfeld Strategic Advisors’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.45M | Sell |
83,916
-97,484
| -54% | -$1.69M | 0.01% | 1068 |
|
|
2025
Q1 | $3.97M | Buy |
+181,400
| New | +$3.97M | 0.02% | 541 |
|
|
2024
Q4 | – | Sell |
-23,839
| Closed | -$688K | – | 1906 |
|
|
2024
Q3 | $688K | Sell |
23,839
-7,727
| -24% | -$223K | ﹤0.01% | 1164 |
|
|
2024
Q2 | $1.21M | Buy |
+31,566
| New | +$1.21M | 0.01% | 998 |
|
|
2023
Q4 | – | Sell |
-1,200
| Closed | -$45.6K | – | 1756 |
|
|
2023
Q3 | $45.6K | Sell |
1,200
-163,003
| -99% | -$6.2M | ﹤0.01% | 1402 |
|
|
2023
Q2 | $15M | Buy |
164,203
+88,176
| +116% | +$8.03M | 0.13% | 250 |
|
|
2023
Q1 | $5.01M | Buy |
76,027
+59,627
| +364% | +$3.93M | 0.05% | 445 |
|
|
2022
Q4 | $848K | Sell |
16,400
-68,289
| -81% | -$3.53M | 0.01% | 1232 |
|
|
2022
Q3 | $5.78M | Sell |
84,689
-13,017
| -13% | -$889K | 0.05% | 487 |
|
|
2022
Q2 | $4.42M | Buy |
+97,706
| New | +$4.42M | 0.04% | 467 |
|
|
2022
Q1 | – | Sell |
-118,558
| Closed | -$5.61M | – | 2368 |
|
|
2021
Q4 | $5.61M | Buy |
118,558
+107,258
| +949% | +$5.07M | 0.05% | 391 |
|
|
2021
Q3 | $373K | Sell |
11,300
-21,234
| -65% | -$701K | ﹤0.01% | 1337 |
|
|
2021
Q2 | $2.06M | Buy |
32,534
+18,533
| +132% | +$1.17M | 0.02% | 666 |
|
|
2021
Q1 | $601K | Sell |
14,001
-24,431
| -64% | -$1.05M | 0.01% | 1039 |
|
|
2020
Q4 | $2.2M | Buy |
+38,432
| New | +$2.2M | 0.03% | 547 |
|
|
2020
Q1 | – | Sell |
-41,067
| Closed | -$1.26M | – | 1123 |
|
|
2019
Q4 | $1.26M | Buy |
+41,067
| New | +$1.26M | 0.03% | 447 |
|
|
2018
Q3 | – | Sell |
-20,771
| Closed | -$457K | – | 776 |
|
|
2018
Q2 | $457K | Buy |
+20,771
| New | +$457K | 0.02% | 558 |
|